CG-2100 is a personal single lead event ECG transtelephonic transmitter. The device is intended for self-testing by patients and records a limited period of heart activity. The recording is activated by patient, when symptom is experienced. CG-2100 enables transmission of the recorded data to a receiving station, where data is displayed for analysis and evaluation by physician. The transmission includes the time, when the event recording was activated by patient. CG-2100 is compatible and intended for use with Telemedicine 2000, the Card Guard's Transtelephonic Receiving Center in its LAN as well as its standalone configuration. The device is intended for self-testing by patients who experience transient symptoms that may suggest cardiac arrhythmia. The device is not intended for simultaneous recording and transmitting of the patient ECG signals.

Device Description

CG-2100 is a personal single lead event ECG transtelephonic transmitter. It has two control buttons: RECORD/SEND and RESET/CLEAR. It has a data storage capacity of 32 Kbyte, sufficient for one ECG event. Transmission is via acoustic transducer. It includes pacemaker detection and marking. The device is internally-powered with applied parts of type BF, suitable for continuous operation. It has low battery detection and audio warning. The user interface includes the control buttons, fluctuating recording sound, fluctuating transmission sound, and low battery warning.

AI/ML Overview

The provided documentation describes the CG-2100 ECG Transmitter and its 510(k) submission, primarily focusing on its substantial equivalence to a predicate device and a list of design control tests. However, it does not contain specific acceptance criteria or a detailed study proving the device meets performance acceptance criteria.

The document outlines design controls and hazard analysis, which include various validation tests (Environmental Tests, Mechanical Vibration, Shock, Surface temperature, Leakage Current, Dielectric Strength, Common Mode Rejection, High and Low Temperature and Humidity, Frequency Response, Input Dynamic Range, Overall System Error, Step Response, Safe Current, System Noise, Ingress of Liquids, and EMC Test). It states that these tests were "conducted to verify and validate the CG-2100 compliance with all the design specifications."

It also mentions that "The conclusions drawn from clinical and laboratory testing of CG-2100 demonstrate that the device is as safe, as effective and performs as well as or better than the legally marketed predicate device, CG-2206 personal ECG transmitter (K963725)."

Without the specific results of these tests and defined acceptance thresholds, it's impossible to create the requested table and answer many of the questions. The document focuses on regulatory compliance through substantial equivalence, rather than a detailed performance study with explicit acceptance criteria.

Therefore, the requested information cannot be fully extracted or inferred from the provided text.

Here's a breakdown of what can be said based on the provided text, and what is missing:

1. Table of Acceptance Criteria and Reported Device Performance:

Acceptance Criteria (Example - Not explicitly stated in document)	Reported Device Performance (Example - Not explicitly stated in document)
(Specific quantitative thresholds for Frequency Response)	(Specific measurements of Frequency Response)
(Specific quantitative thresholds for System Noise)	(Specific measurements of System Noise)
(Specific pass/fail criteria for environmental tests)	(Confirmation of passing all environmental tests)
Performance equivalent to predicate device (CG-2206)	"as safe, as effective and performs as well as or better than the legally marketed predicate device"

Missing Information: The document lists types of tests conducted (e.g., "Frequency Response Test," "Overall System Error Test"). However, it does not specify the acceptance criteria (quantitative thresholds or pass/fail conditions) for these tests, nor does it provide the actual reported device performance results against these criteria. It only states that the tests were conducted to "verify and validate the CG-2100 compliance with all the design specifications."

2. Sample Size Used for the Test Set and Data Provenance:

Missing Information: The document does not provide details on the sample size used for any specific performance testing (such as a test set for a clinical study or a technical validation). It mentions "clinical and laboratory testing" but no specifics on patient numbers, demographics, or data origin (country of origin, retrospective/prospective).

3. Number of Experts and their Qualifications for Ground Truth:

Missing Information: This information is not present in the document. The device is a "single lead event ECG transtelephonic transmitter" intended for physician analysis of recorded data, implying that a physician would interpret the ECG. However, there's no mention of experts establishing a ground truth for a test set.

4. Adjudication Method for the Test Set:

Missing Information: No adjudication method is mentioned as there is no described study involving multiple readers or complex diagnostic tasks requiring adjudication.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

Missing Information: There is no indication of an MRMC study being conducted, nor any quantification of human reader improvement with or without AI assistance. The device itself is an ECG transmitter, not an AI-powered diagnostic tool.

6. Standalone (Algorithm Only) Performance Study:

Missing Information: The device's function is to transmit ECG data for a physician to analyze. It is not an automated diagnostic algorithm that would have a "standalone" performance evaluation in the context of AI. The document describes laboratory tests for the transmitter's technical specifications, but these are not evaluating an algorithm's diagnostic performance.

7. Type of Ground Truth Used:

Missing Information: Since no specific performance study with a test set is detailed, the type of ground truth used is not described. For a device like this, the ground truth for performance might involve comparing transmitted ECGs to reference ECG recordings, or evaluating the accuracy of technical specifications against established standards. The document primarily refers to compliance with standards (e.g., ANSI/AAMI EC38-D) and design specifications.

8. Sample Size for the Training Set:

Missing Information: There is no mention of a "training set" as this device does not appear to utilize machine learning or AI that would require a training phase.

9. How the Ground Truth for the Training Set Was Established:

Missing Information: Not applicable, as there is no mentioned training set.

Summary

{0}------------------------------------------------

	DEC 21 1999	K994009
CARD GUARD Scientific Survival LTD	CG-2100 ECG Transmitter 510(k) Summary of Safety and Effectiveness
Submitter:	Card Guard Scientific Survival Ltd., 2 Pekeris St. P.O.B. 527 Rehovot 76100, Israel Tel: 972-8-9484600 Fax: 972-8-9484605
Contact Person:	Leonid Trachtenberg, Chief Engineer, Tel: 972-8-9484624 E-mail: ltrachtenberg@cardguard.com
Date Prepared:	November 22, 1999

Definition and Intended Use 1.
CG-2100 is a personal single lead event ECG transtelephonic transmitter. The device is intended for self-testing by patients and records a limited period of heart activity. The recording is activated by patient, when symptom is experienced.

CG-2100 enables transmission of the recorded data to a receiving station, where data is displayed for analysis and evaluation by physician. The transmission includes the time, when the event recording was activated by patient.

CG-2100 is compatible and intended for use with Telemedicine 2000, the Card Guard's Transtelephonic Receiving Center in its LAN as well as its standalone configuration.

CG-2100 is classified as Class II medical device.

Applicable Standards, Regulations, Guidances 2.

CG-2100 Transmitter meets the requirements of the following Standards, Regulations and Guidances:

CFR Title 21 Part 820 Quality System Regulation, Medical Devices, published in . Federal Register, 61 RF 52602 - October 7, 1996
ANSI/AAMI EC38-D, "Ambulatory Electrocardiograph", 1994 .
ANSI/AAMI EC13 Cardiac Monitors, HR Meters and Alarms, 2nd edition 1992 .
ANSI/AAMI EC1-1993, "Safe Current Limits for Electromedical Apparatus" Dec 1993 .
ANSI/AAMI EC11 Diagnostic Electrocardiographic Devices, 2nd edition 1991 .
ANSI/AAMI EC53-1995 "ECG Cables and Leadwires". .
EN1441: 1997 Medical Devices Risk Analysis, .
IEC 1025: 1990 Fault tree analysis (FTA) .
IEC/TR 513: 1994 Fundamental aspects of safety standards for medical ● electrical equipment
IEC 801-1, 1984, "General Introduction" .
IEC 601-1, 1996, "Medical Electrical Equipment, Part I General Requirements for . Safety"
IEC 601-1-1, 1996, "Safety Requirements for Medical Electrical Systems" .
IEC 601-1-2, 1993, "Part 2: Electromagnetic compatibility-Requirements and Tests" .

This document contains proprietary information of	Document No.	Rev.	Page	of
CARD GUARD Scientific Survival Ltd.and of the promoted of the promote of the program and the commend of the many of the many of the may of the may be one of the comments of the may of the may be any and	N/A	N/A

{1}------------------------------------------------

Image /page/1/Picture/0 description: The image shows the words "CARD GUARD" in bold, black letters. Underneath the words "CARD GUARD" is the phrase "Scientific Survival LTD" in a smaller font. To the right of the text is a black line that resembles a heart rate monitor.

CG-2100 ECG Transmitter

510(k) Summary of Safety and Effectiveness

IEC 601-1-4, 1996, "Part 1-4, Programmable Electrical Medical Systems" ●
IEC 801-2, 1991. "Electrostatic Discharge Requirements' .
IEC 801-3, 1992, "Immunity to Radiated Radiofrequency electromagnetic fields" ●
IEC 801-4, 1988. "Electrical Fast Transient Burst Requirements" .
IEC 812: 1985 Analysis techniques for system reliability -- Procedure for failure . mode and effects analysis (FMEA)
IEC 300-3-9: 1995 · Dependability management, Part 3: Application guide -. Section 9, Risk analysis of technological systems
CISPR 11 1990 "Limits and Methods of Measurement of Electromagnetic . Disturbance Characteristics of Industrial, Scientific and Medical (ISM) Radio frequency Equipment" 2nd Edition
"Reviewer Guidance for Computer Controlled Medical Devices", FDA Aug 29, 1991 ●
ISO/IEC Guide 51: 1990 Guidelines for the inclusion of safety aspects in standards ●
ISO 9002 guidelines .
EN-46002 .
IEEE Standard for Software Qualitv Assurance Plan .
FDA's Guidance for the Content of Premarket Submissions for Software . Contained in Medical Devices, May 29, 1998
FDA's "New 510(k) Paradigm, Alternate Approaches to Demonstrating Substantial . equivalence in Premarket Notifications" Final Guidance, CDRH, March 20, 1998.

3. Features

Two control buttons: RECORD/SEND and RESET/CLEAR. .
Data storage capacity 32 Kbyte, sufficient for one ECG event. .
Transmission via acoustic transducer. .
Pacemaker detection and marking. .
The device shall be internally-powered with applied parts of type BF, suitable for . continuous operation.
. Low Battery detection and audio warning

4. User Interface

The CG-2100 user interface incorporates the following controls and signals:

. RECORD/SEND control button
. RESET/CLEAR control button
Fluctuating recording sound ending with a wavy tone (approximately 30 seconds). .
Fluctuating transmission sound (approximately 10 second). .
Low battery warning (three sequential beeps). ●

This document contains proprietary information ofCARD CHARD Scientific Survival ltd	Document No.	Rev.	Page	of
	N/A	N/A	2	3

{2}------------------------------------------------

5. Substantial Equivalence

CARD GUARI

The CG-2100 single lead event ECG transtelephonic transmitter, the subject of this submission, is a simplified version of the CG-2206 personal ECG transmitter (K963725). Therefore the CG-2100 is equivalent to its predicate device: the CG-2206.

CG-2100 and its predicate device. CG-2206, have the following qualities in common:

. The same intended use, and
. The same principles of operation, features and technological characteristics.

6. Material differences

CG-2606 has a Common input whereas CG-2100 has none. .
CG-2100 has a 32 Kbyte Memory, as compared to CG-2606 128 Kbyte. .

7. Design Controls and Hazard Analysis

The Card Guard's product design procedure, and OA and OC policy, formalize the design and production process and assure that all respective requirements are met. In the framework of the Design Controls the laboratory testing was conducted to verify and validate the CG-2100 compliance with all the design specifications. This included:

Validation tests

Environmental Tests

Mechanical Vibration Shock Test

Surface temperature Test

Leakage Current Test

Dielectric Strength Test

Common Mode Rejection Test High and Low Temperature and Humidity Test . .
.

. Frequency Response Test
. Input Dynamic Range Test
. Overall System Error Test
Step Response Test .

Safe Current Test

System Noise Test .
.
Ingress of Liquids Test . EMC Test
The device biocompatibility was evaluated and found to be satisfactory.

The device Level of Concern criteria were evaluated and CG-2100 was characterized as a moderate level of concern system.

The System Safety and Risk analysis conducted for CG-2100 provided rigorous design and structural evaluation aimed at revealing potential failures or possible system flaws which could directly or indirectly effect the patient.

8. Conclusions

CG-2100 ECG Transmitter, constitutes a safe and reliable means for recording and transmitting standard ECG for the purpose of cardiac condition diagnosis. Its material composition and of operation present no adverse health effect or safety risks to patients when used as intended.

The conclusions drawn from clinical and laboratory testing of CG-2100 demonstrate that the device is as safe, as effective and performs as well as or better than the legally marketed predicate device, CG-2206 personal ECG transmitter (K963725).

This document contains proprietary information ofCARD GUARD Scientific Survival Ltd.	Document No.N/A	Rev.N/A	Page	of3
			3

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three curved lines.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

DEC 2 1 1999

Leonid Trachtenberg Chief Engineer Card Guard Scientific Survival Ltd. 2 Pekeris St. P.O.B. 527 Rehobot 76100, Israel

Re: K994009 CG-5100 ECG Transmitter Regulatory Class: II (two) Product Code: DXH Dated: November 17, 1999 Received: November 26, 1999

Dear Mr. Trachtenberg:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{4}------------------------------------------------

Page 2 - Mr. Leonid Trachtenberg

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Celia M. Witten, Ph.D., M.

elia M. Witten, Ph.D., M.D. Acting Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

CARD GUARD
Scientific Survival LTD

CG-2100 ECG Transmitter. Special 510(k) Premarket Notification

The device is intended for self-testing by patients who experience transient symptoms that may suggest cardiac arrhythmia.

The device is not intended for simultaneous recording and transmitting of the patient ECG signals.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use
(Per 21 CFR 801.109)
OR

Over-The-Counter Use

(Optional Format 1-2-96)

Doub Tle

(Division Sign-Off) Division of Cardiovascular, Respiratory, and Neurological Devices વધુ મુજરાત

510(k) Number.

Regulation Number and Section

§ 870.2920 Telephone electrocardiograph transmitter and receiver.

(a)
Identification. A telephone electrocardiograph transmitter and receiver is a device used to condition an electrocardiograph signal so that it can be transmitted via a telephone line to another location. This device also includes a receiver that reconditions the received signal into its original format so that it can be displayed. The device includes devices used to transmit and receive pacemaker signals.(b)
Classification. Class II (performance standards).